US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles
The fightback begins: Boss of London's Queen Mary University tells pro
A university boss has been praised after telling a pro-Gaza student mob he will not meet them until2024-05-21Village Super League, new gala for ethnic culture in SW China
(Xinhua) 08:32, January 16, 2024Players compete during a match of the new season of Chinese football2024-05-21Chinese City of Youth, Chengdu, Bracing for World University Games
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21Exhibition Featuring Paintings by Children of Xinjiang Held in Beijing
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21California congressman urges closer consultation with tribes on offshore wind
A congressman who represents California’s north coast has sent a letter to federal regulators asking2024-05-21Arxan in N China's Inner Mongolia: An Increasingly Popular Tourist Destination
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21
atest comment